Sarepta Therapeutics (SRPT) FY2019 results: revenue $381 million, up 26.5% on the year
Sarepta Therapeutics, Inc. (SRPT) reported revenue of $381 million for fiscal 2019, the year ended 31 December 2019, up 26.5% on the year before. Net income was -$715 million, and diluted earnings per share $-9.71. The figures are the company's own, from the 10-K it filed with the SEC on 26 February 2020.
Revenue
$381 million
+26.5% on the year
FY2014FY2019
Operating margin
-185.3%
-114.1% a year earlier
FY2014FY2019
Net income
-$715 million
FY2014FY2019
Diluted EPS
-$9.71
FY2014FY2019
this yearthe year beforeHover a bar for its figure.
The year in brief
Income statement (profit and loss)
$ million
FY2019
FY2018
FY2017
On the year
Last 8 years
Revenue
381
301
155
+26.5%
Research and development
561
402
167
+39.6%
Selling, general and administrative
285
208
123
+37.1%
Operating income
-706
-344
-172
Operating margin
-185.3%
-114.1%
-111.0%
Interest expense
30.7
33.7
5.8
-9.0%
Pre-tax income
-714
-363
-48.6
Income tax
1.2
-0.7
2.1
Net income
-715
-362
-50.7
Net margin
-187.8%
-120.2%
-32.8%
Diluted EPS
-$9.71
-$5.46
-$0.86
$ million except per share. Read moreFree cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.
Cash flow
$ million
FY2019
FY2018
FY2017
On the year
Last 8 years
Operating cash flow
-456
-389
-232
Capital expenditure
59.6
61.2
12.0
-2.5%
Free cash flow
-516
-450
-244
Free cash flow margin
-135.5%
-149.4%
-157.8%
Cash from investing
287
-370
-179
Cash from financing
643
530
888
+21.2%
Depreciation and amortisation
24.5
12.2
8.1
+100.1%
Share-based compensation
78.6
50.1
30.5
+56.8%
Diluted shares, weighted
74m
66m
59m
+11.1%
Shares outstanding at period end
75m
71m
65m
+5.8%
Balance sheet
$ million
FY2019
FY2018
FY2017
On the year
Last 8 years
Shareholders' equity
818
1,032
789
-20.7%
Debt
682
421
431
+62.1%
Operating lease liabilities
47.7
n/a
n/a
Other liabilities
275
189
87.7
+45.3%
Total liabilities and equity
1,823
1,642
1,308
+11.0%
Fixed assets
130
97.0
43.2
+33.6%
Intangible assets
12.5
11.6
14.4
+8.0%
Investments
290
803
489
-63.9%
Cash and equivalents
835
371
600
+125.2%
Receivables
90.9
49.0
29.5
+85.3%
Inventory
171
125
83.6
+36.6%
Other assets
294
185
48.3
+58.7%
Total assets
1,823
1,642
1,308
+11.0%
10-K for the year ended 31 December 2019, filed 26 February 2020: the filing.